



Medgate to pilot ResApp's ResAppDx for telehealth across Europe

- **Medgate is a leading provider of digital health and telemedicine services and operates Europe's largest telemedical centre**
- **Agreement to integrate and test ResAppDx in Medgate's services – pilot program to commence in early 2021**
- **Provides additional validation of ResApp's technology and offering**

Brisbane, Australia, 9 November 2020 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has signed a six-month joint development and pilot agreement with Medgate AG ("Medgate") to integrate and test ResApp's smartphone-based acute respiratory diagnostic test ResAppDx in Medgate's telemedicine services.

Medgate is a leading provider of telehealth services. Since 2000, Medgate has been operating Europe's largest telemedical centre in Switzerland, and employs over 500 employees worldwide, including over 200 physicians.

Medgate and ResApp will work together to build and pilot an integration of ResAppDx in the Medgate services. The integration phase of the project, which covers both technical integration and clinical workflows, is expected to take two months, with a three-month pilot period to evaluate the integration expected to begin in early 2021. During the pilot phase, ResApp and Medgate will jointly assess the impact of ResAppDx on Medgate's telehealth service through a number of key performance indicators.

During the pilot, ResApp and Medgate expect to enter into negotiations on the cost model of using ResAppDx on Medgate's telehealth service.

ResApp will not receive material revenue from the pilot project. Either party may terminate the joint development and pilot agreement by providing 30 days' notice.

CEO and Managing Director Dr Tony Keating said: *"We are very pleased to have entered into this pilot agreement with such a high calibre partner. Medgate is a well-known and respected organisation and we look forward to working with them to deliver our ResAppDx product to their customers.*

"This partnership is ongoing validation of our offering and will potentially allow the company to pursue a large market opportunity in Europe, as well as in Asia and the Middle East where Medgate also has



operations. I look forward to updating shareholders on the integration and commencement of the pilot initiative in the coming months."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Medgate

Medgate brings the physician to where he or she is needed by patients and relies on Digital Health solutions to do so. The focus is on the well-being of the patient and the benefits to society. Medgate was founded in Switzerland in 1999 and today employs over 510 people worldwide. Since 2000, Medgate has been operating the largest medical telemedicine center in Europe and thus has an extraordinary amount of experience and knowledge in telemedicine. Medgate is also present in Germany, the Philippines, the United Arab Emirates and India. www.medgate.care

Contacts for ResApp Health

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.